Resistance associated mutations (RAMs) threaten the long-term success of combination antiretroviral 19 therapy (cART) outcomes for HIV-1 treatment. HIV-1 Integrase (IN) strand transfer inhibitors (INSTIs) 20 have proven to be a viable option for highly specific HIV-1 therapy. The INSTI, Dolutegravir is 21 recommended by the World Health Organization for use as first-line cART. This study aims to understand 22 how RAMs affect the stability of IN, as well as the binding of the drug Dolutegravir to the catalytic 23 pocket of the protein. Molecular modelling of HIV-1C IN was performed using the SWISS-MODEL 24 webserver; with quality assessment performed using internal methods and external software tools. The 25 site directed mutator webserver was used to predict destabilizing and/or stabilizing effects of known 26 RAMs while FoldX confirmed any changes in protein energy upon introduction of mutation. Interaction 27 analysis between neighbouring residues was done using PyMOL. Three randomly selected mutations 28 were chosen for molecular dynamic simulation studies using Gromacs. Trajectory analysis included Root 29 mean square deviation and fluctuation, Radius of gyration, Principal component analysis and Interaction 30 analysis between Dolutegravir and protein residues. The structural quality assessment indicated high 31 reliability of the HIV-1C IN tetrameric structure, with more than 90% confidence in modelled regions.
Introduction 40
The Integrase (IN) enzyme plays an important role in the Human Immunodeficiency Virus type 1 (HIV-1) 41 replication cycle by catalysing two distinct reactions termed: 3'-end processing and strand transfer.
42
During the 3' processing, IN removes two nucleotides from the 3' ends of both viral DNA strands and 43 exposes the C-alpha hydroxyl group on the 3'ends. The subsequent step involves strand transfer whereby,
44
IN attacks the phosphodiester backbone of the host DNA and links the exposed 3'-end to the 5' hydroxyl 54 Furthermore, a recent study provided evidence for the replacement of RAL with DTG based on the low 55 prevalence of DTG resistance and the low risk for INSTI mutations when patients are on DTG treatment 56 [8] . Although BIC has been recently approved, not much information is known about it and as a result,
57
DTG still remains the preferred option.
58
The functional mechanism of INSTIs is to bind to the catalytically essential magnesium ions, thereby software FoldX was used to predict the change in Gibbs free energy after the introduction of the mutation.
118
We also calculated the loss or gain of polar interactions between neighbouring residues located adjacent 119 to the mutation using PyMOL [21] .
121

Molecular dynamic simulation 122
For simulation studies we only considered the two inner dimers of the protein structure, as the other two 123 monomers were similar in sequence and structure. Three different mutant systems were prepared by 124 introducing a specific mutation into the WT structure through the mutagenesis wizard in PyMOL and 125 energy minimizing the structures using Gromacs [20]. The WT and three mutant systems (E92Q, S140 each monomer labelled and colour coded. The VERIFY 3D score was 80.1%, the ERRAT overall quality 171 score was 90% and higher for all four chains (A, B, C and D) and the Ramachandran plot indicated more 172 than 90% of residues fell within the most favoured regions of the plot suggesting the predicted structure is 173 a reliable model. Stability predictions indicated 15 RAMs to be destabilizing and five to be stabilizing for the protein structure based on SDM delta-delta G free energy scores ( respectively. Interaction analysis showed ten mutations resulted in a loss of polar contacts; three resulted 178 in an increase in polar contacts, while seven showed no change in the number of polar contacts with 179 neighbouring residues (Table 1) . 
191
The number in front of brackets is the total amount of interactions. Abbreviations of amino acids: A - the drug DTG. Trajectory analysis of the RMSD of the backbone indicated that the WT system reached 198 equilibrium after 100 ns as well as the Q92, R143 and S140 mutant systems (Fig 2A) . Only S140 showed 199 higher RMSD fluctuation values compared to the WT, R143 and Q92 systems (Fig 2A) . RMSF analysis 200 clearly showed higher flexibility for the S140 mutant system, with four highly flexible regions (residues 201 68 -70, 142 -146, 166 -170 and 253 -256) compared to the WT, Q92 and R143 systems ( Fig 2B) . These 202 flexible regions affect the 140's loop region that regulates drug binding. The Radius of gyration values 203 indicated decreasing values for R143 and E92 compared to the WT and S140 mutant system ( Fig 2C) .
204
Plotting the first two principal components provided insight into the collective movement of each protein 205 atom. The 2D projections of the first and second principal components for the WT, Q92, R143 and S140 206 systems are shown in Figure 2D . Calculation of the covariance matrix values after diagonalization 207 showed a significant increase for the S140 system (18.33 nm) compared to the other three systems WT,
208
Q92 and R143 each having 9.58 nm, 8.98 nm and 10.41 nm lower values, respectively. Distance analysis 209 indicated a smaller average distance of 0.21  0.01 nm and 0.22  0.01 nm between the WT, R143 MG 210 ion and drug DTG systems compared to Q92 and S140 each having a distance of 0.41  0.04 nm, 0.99  211 0.20 nm, respectively ( Fig 2D) . 
214
(A) Change in backbone RMSD for the WT, Q92, S140 and R143 systems plotted over 300 ns. (B)
215
Change in RMSF for the C-alpha residues for the WT, Q92, S140 and R143 systems plotted over the last Interaction analysis 221 We performed interaction analysis for five snapshots (every 50 ns) of each of the simulation systems to 222 determine which residues played a role in the binding of DTG to the protein in the WT and mutant protein 223 structures. For the WT system, interactions were observed between known active site residues D64, D116
224 and N148, MG ion and also to DNA nucleotides (Table 2) . Similarly, interactions were observed between 225 known active site residues D64, R143, N148, MG ion and DNA nucleotides for the R143 system (Table   226 2). Interestingly, no active site residue interactions between DTG and S140 structure was observed and no 227 MG ionic interactions for S140. Only the Q92 system showed interactions with active site residues but no 228 MG ionic interactions ( . We randomly selected three mutations Q92, 256 S140 and R143 to investigate the role of amino acid substitutions on protein structure and drug binding in 257 comparison to the WT protein structure. Analysis of the change in trajectory of the mutant systems 258 compared to the wild type suggested less stability and higher fluctuation of the G140S mutant system 259 compared to the WT system. We also confirmed the destabilizing effect of the G140S mutant using 260 principal component analysis which suggested larger randomized concerted movement for the G140S 261 mutant compared to the WT, Q92 and R143 systems. These findings are similar to Chen et al.
[10] which 262 showed that the G140S mutations can either stabilize or destabilize the 140's loop region. In our case, the 263 140's loop region is stabilized by the G140S mutation that could prevent drug binding. This is supported 264 by pairwise distance analysis confirming a larger distance between the MG ion and drug DTG for the 265 G140S mutant system compared to the WT and R143. Further interaction analysis was performed to 266 confirm the hypothesis that the S140 mutation could prevent drug binding by extracting structures at 267 different snapshots of the simulation. Here, we found that the G140S mutation resulted in the drug being 268 expelled from the binding pocket. We also observed weaker interactions for the Q92 mutation but 269 stronger interactions for R143 mutant. The findings from our study suggest that patients should first be 270 screened for mutations and or novel variants to determine if the drug DTG will be efficacious or not. The
271
model generated in this study can be used to tease out the effects of novel variants. A few limitations of 272 this study are the use of RAL, EVG mutants and not considering novel RAL or DTG mutations. We also 273 only simulated single mutations instead of double however we have yet to identify double mutants within 274 the South African cohort of HIV-1C infected patients. Future work will include viral fitness assays to 275 determine the effect of the mutant S140 on the HIV-1C virus and the effect of the drug DTG on the virus 276 ability to persist in the presence of the drug. 
